References:
1. Stirrat GM. Recurrent miscarriage. Lancet 1990;336:673–5
(PMID:26663220).
2. Practice Committee of American Society for Reproductive Medicine.
Evaluation and treatment of recurrent pregnancy loss: a committee
opinion. Fertil Steril 2012Nov; 98(5):1103-11 (PMID:23095139).
3. Johns J, Muttukrishna S, Lygnos M, Groome N, Jauniaux E. Maternal
serum hormone concentrations for prediction of adverse outcome in
threatened miscarriage. Reprod Biomed Online 2007;15(4):413–421
(PMID:17908404).
4. Guha S, Van Belle V, Bottomley C, Preisler J, Vathanan V, Sayasneh A,
et al. External validation of models and simple scoring systems to
predict miscarriage in intrauterine pregnancies of uncertain viability.
Hum Reprod 2013;28(11):2905–11 (PMID:23980057).
5. Al Mohamady M, Fattah GA, Elkattan E, Bayoumy R, Hamed DA.
Correlation of serum CA-125 and progesterone levels with ultrasound
markers in the prediction of pregnancy outcome in threatened
miscarriage. Int J Fertil Steril 2016;9(4):506–11 (PMID:26985338).
6. Pillai RN, Konje JC, Tincello DG, Potdar N. Role of serum biomarkers
in the prediction of outcome in women with threatened miscarriage: a
systematic review and diagnostic accuracy meta-analysis. Hum Reprod
Update 2016; 22(2):228–39.
7. Arck P, Hansen PJ, Mulac Jericevic B, Piccinni MP, Szekeres-Bartho J.
Progesterone during pregnancy: endocrine-immune cross talk in mammalian
species and the role of stress. Am J Reprod Immunol 2007; 58(3):268–79
(PMID:17681043).
8. Schwartz N, Xue X, Elovitz MA, Dowling O, Metz CN. Progesterone
suppresses the fetal inflammatory response ex vivo. Am J Obstet Gynecol
2009;201:211.e1.9 (PMID:19646573).
9. Adam Czyzyk, Agnieszka Podfigurna, Andrea Riccardo Genazzani, Blazej
Meczekalski. The role of progesterone therapy in early pregnancy: from
physiological role to therapeutic utility. Gynecol Endocrinol 2017;
33(6): 421–424 (PMID:28277122).
10. Carmona F, Balasch J, Creus M, Fábregues F, Casamitjana R, Cívico S,
et al. Early hormonal markers of pregnancy outcome after in vitro
fertilization and embryo transfer. J Assist Reprod Genet
2003;20:521–526 (PMID:15035553).
11. Duan L, Yan D, Zeng W, Yang X, Wei Q. Predictive power progesterone
combined with beta human chorionic gonadotropin measurements in the
outcome of threatened miscarriage. Arch Gynecol Obstet 2011;283:431-435
(PMID:20107822).
12. Liu Y, Liu Y, Li X, Jiao X, Zhang R, Zhang J. Predictive value of
serum β-hCG for early pregnancy outcomes among women with recurrent
spontaneous abortion. Int J Gynaecol Obstet 2016Oct; 135(1):16-21
(PMID:27567433).
13. Hildebrandt VA, Babischkin JS, Koos RD, Pepe GJ, Albrecht ED.
Developmental regulation of vascular endothelial growth/permeability
factor messenger ribonucleic acid levels in and vascularization of the
villous placenta during baboon pregnancy. Endocrinology 2001; 142:
2050–57 (PMID:11316772).
14. Tanriverdi F, Silveira LF, Maccoll GS, Bouloux PM. The
hypothalamic-pituitary-gonadal axis: Immune function and autoimmunity. J
Endocrinol 2003; 176: 293–304 (PMID:12630914).
15. Xu Q, Chen J, Wei Z, Brandon TR, Zava DT, Shi YE, et al. Sex Hormone
Metabolism and Threatened Abortion. Med Sci Monit 2017; 23: 5041-5048
(PMID:29056745).
16. Lin Y, Liu C. Prediction of early pregnancy outcomes. Int J Gynaecol
Obstet 1995; 51:33–38 (PMID:8582515).
Acknowledgments: The research was supported by the Medical and
Health Science and Technology Plan Project of Zhejiang
Province(2020KY827)
Declaration of interest statement: The authors report no
conflict of interest.
Table 1. Comparison of E2 and β-HCG levels between ongoing pregnancy
group and inevitable abortion group